PRAX – Praxis Precision Medicines Inc
Praxis Precision Medicines, IncPRAX
$250.33Name : Praxis Precision Medicines, Inc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $6,978,893,312.00
EPSttm : -13.39
Praxis Precision Medicines, Inc
$250.33
1.15%$2.92
PRAX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
14.2
Margin Of Safety %
Put/Call OI Ratio
5.08
EPS Next Q Diff
-0.85
EPS Last/This Y
-1.79
EPS This/Next Y
5.09
Price
250.25
Target Price
621.76
Analyst Recom
1.41
Performance Q
-19.22
Upside
-287.1%
Beta
2.82
Ticker: PRAX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | PRAX | 331.18 | 4.38 | 999.99 | 11121 |
| 2026-05-12 | PRAX | 343.37 | 4.38 | 0.52 | 11125 |
| 2026-05-13 | PRAX | 346.56 | 4.22 | 1.14 | 11279 |
| 2026-05-14 | PRAX | 345.33 | 4.20 | 1.07 | 11361 |
| 2026-05-15 | PRAX | 343.58 | 4.21 | 1.26 | 11343 |
| 2026-05-18 | PRAX | 321.17 | 5.57 | 0.34 | 9352 |
| 2026-05-19 | PRAX | 321.12 | 6.10 | 0.69 | 9292 |
| 2026-05-20 | PRAX | 335.45 | 6.06 | 0.12 | 9309 |
| 2026-05-21 | PRAX | 350.3 | 6.04 | 0.07 | 9316 |
| 2026-05-22 | PRAX | 343.54 | 5.96 | 1.94 | 9339 |
| 2026-05-26 | PRAX | 349.87 | 5.94 | 2.92 | 9375 |
| 2026-05-27 | PRAX | 357 | 5.95 | 0.08 | 9401 |
| 2026-05-28 | PRAX | 352.4 | 5.92 | 0.03 | 9411 |
| 2026-05-29 | PRAX | 349.98 | 5.80 | 0.10 | 9441 |
| 2026-06-02 | PRAX | 257.62 | 5.67 | 1.34 | 9481 |
| 2026-06-03 | PRAX | 278.95 | 5.78 | 0.47 | 9743 |
| 2026-06-04 | PRAX | 265.08 | 5.44 | 0.75 | 9866 |
| 2026-06-05 | PRAX | 253.98 | 5.43 | 0.54 | 9872 |
| 2026-06-08 | PRAX | 252.99 | 5.34 | 0.20 | 9884 |
| 2026-06-09 | PRAX | 249.83 | 5.08 | 0.67 | 9960 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | PRAX | 331.06 | -11.8 | - | -15.23 |
| 2026-05-12 | PRAX | 343.31 | -10.6 | - | -15.01 |
| 2026-05-13 | PRAX | 346.51 | -10.6 | - | -15.01 |
| 2026-05-14 | PRAX | 345.30 | -12.7 | - | -15.07 |
| 2026-05-15 | PRAX | 341.89 | -12.7 | - | -15.07 |
| 2026-05-18 | PRAX | 320.87 | -12.6 | - | -14.99 |
| 2026-05-19 | PRAX | 320.89 | -12.6 | - | -14.99 |
| 2026-05-20 | PRAX | 335.56 | -11.4 | - | -15.11 |
| 2026-05-21 | PRAX | 350.30 | -11.4 | - | -15.11 |
| 2026-05-22 | PRAX | 343.50 | -11.4 | - | -15.11 |
| 2026-05-26 | PRAX | 350.05 | -11.4 | - | -15.11 |
| 2026-05-27 | PRAX | 357.34 | -11.4 | - | -15.11 |
| 2026-05-28 | PRAX | 352.41 | -11.6 | - | -15.12 |
| 2026-05-29 | PRAX | 349.88 | -11.6 | - | -15.12 |
| 2026-06-01 | PRAX | 335.20 | -11.6 | - | -15.12 |
| 2026-06-02 | PRAX | 259.77 | -11.6 | - | -15.12 |
| 2026-06-03 | PRAX | 278.92 | -11.6 | - | -15.12 |
| 2026-06-04 | PRAX | 264.90 | -11.6 | - | -15.12 |
| 2026-06-05 | PRAX | 253.99 | -11.6 | - | -15.12 |
| 2026-06-08 | PRAX | 252.91 | -12.1 | - | -15.27 |
| 2026-06-09 | PRAX | 250.25 | -12.1 | - | -15.27 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | PRAX | -2.26 | 11.49 | 14.42 |
| 2026-05-12 | PRAX | -2.26 | 11.49 | 14.41 |
| 2026-05-13 | PRAX | -2.26 | 11.49 | 14.41 |
| 2026-05-14 | PRAX | -2.26 | 11.49 | 14.41 |
| 2026-05-15 | PRAX | -2.26 | 11.49 | 14.41 |
| 2026-05-18 | PRAX | -2.26 | 12.86 | 14.41 |
| 2026-05-19 | PRAX | -2.26 | 12.86 | 14.41 |
| 2026-05-20 | PRAX | -2.26 | 12.86 | 14.41 |
| 2026-05-21 | PRAX | -2.26 | 12.86 | 14.41 |
| 2026-05-22 | PRAX | 0.00 | 12.86 | 14.47 |
| 2026-05-26 | PRAX | 0.00 | 6.40 | 14.47 |
| 2026-05-27 | PRAX | 0.00 | 6.40 | 14.47 |
| 2026-05-28 | PRAX | 0.00 | 6.40 | 14.21 |
| 2026-05-29 | PRAX | 0.00 | 6.40 | 14.21 |
| 2026-06-02 | PRAX | 0.00 | 5.72 | 14.21 |
| 2026-06-03 | PRAX | 0.00 | 5.72 | 14.21 |
| 2026-06-04 | PRAX | 0.00 | 5.72 | 14.21 |
| 2026-06-05 | PRAX | 0.00 | 5.72 | 14.21 |
| 2026-06-08 | PRAX | 0.00 | 5.73 | 14.20 |
| 2026-06-09 | PRAX | 0.00 | 5.73 | 14.20 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-3.2
Avg. EPS Est. Current Quarter
-3.71
Avg. EPS Est. Next Quarter
-4.05
Insider Transactions
Institutional Transactions
5.73
Beta
2.82
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
11
Growth Score
23
Sentiment Score
53
Actual DrawDown %
31.7
Max Drawdown 5-Year %
-96.5
Target Price
621.76
P/E
Forward P/E
PEG
P/S
P/B
4.95
P/Free Cash Flow
EPS
-13.38
Average EPS Est. Cur. Y
-15.27
EPS Next Y. (Est.)
-10.18
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.98
Return on Equity vs Sector %
-50.6
Return on Equity vs Industry %
-34.5
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.04
EBIT Estimation
◆
PRAX
Healthcare
$250.33
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
30.5
Range 1M
4.3%
Sup Dist
2.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-12.9%
EPS NY
28.3%
52W%
64.5%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+148.4% upside
Upside
+148.4%
Quality
11
Praxis Precision Medicines, IncSector: Healthcare
Industry: Biotechnology
Employees: 168
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
PRAX
Latest News
—
Caricamento notizie per PRAX…
stock quote shares PRAX – Praxis Precision Medicines Inc Stock Price stock today
news today PRAX – Praxis Precision Medicines Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PRAX – Praxis Precision Medicines Inc yahoo finance google finance
stock history PRAX – Praxis Precision Medicines Inc invest stock market
stock prices PRAX premarket after hours
ticker PRAX fair value insiders trading